Investigational New Drugs

, Volume 33, Issue 1, pp 194–200 | Cite as

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours

  • Haruo Iguchi
  • Tomohiro Nishina
  • Naoyuki Nogami
  • Toshiyuki Kozuki
  • Yumiko Yamagiwa
  • Katsuro Yagawa


Purpose This Phase I, open-label, single-arm, dose-escalation study aimed to evaluate the safety and tolerability of the insulin-like growth factor (IGF-I/II) neutralizing antibody, MEDI-573, in Japanese patients with advanced solid tumours refractory to standard therapy or for which no standard therapy exists. The pharmacokinetics, pharmacodynamics and antitumour activity of MEDI-573 were also evaluated. Methods Three cohorts of patients received MEDI-573 in escalating order: cohort 1, 5 mg/kg on Day 1, 8 and 15; cohort 2, 15 mg/kg on Day 1, 8 and 15; cohort 3, 45 mg/kg on Day 1, of 21-day cycles. Results Ten patients who received at least one dose of MEDI-573 were evaluated. The median number of treatment cycles was 2.0 (range 1–6) and the median number of MEDI-573 doses received was 4.0 (range 1–17). The most commonly reported drug-related adverse events were fatigue (n = 2 patients), pyrexia (n = 2), diarrhoea (n = 2) and electrocardiogram QT prolongation (n = 2). No patients experienced a dose-limiting toxicity. Pharmacokinetics of MEDI-573 were linear with a dose-dependent increase. There were no complete or partial responses; four patients had an overall best response of stable disease. Conclusions MEDI-573 is well tolerated at the doses investigated.


Novel antitumour agent IGF-II/I inhibitor MEDI-573 Monoclonal antibody Phase I Solid tumours 



This study was sponsored by AstraZeneca. Writing assistance was provided by Claire Routley, PhD, from Mudskipper Business Ltd, funded by AstraZeneca.

Conflicts of interest

Tomohiro Nishina, Naoyuki Nogami, Yumiko Yamagiwa and Haruo Iguchi have no conflicts of interest to declare. Toshiyuki Kozuki has received honoraria from AstraZeneca KK. Katsuro Yagawa is an employee of AstraZeneca KK.

Supplementary material

10637_2014_170_MOESM1_ESM.doc (32 kb)
ESM 1 (DOC 32 kb)


  1. 1.
    Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16:2512–2517PubMedCrossRefGoogle Scholar
  2. 2.
    Arnaldez FI, Helman LJ (2012) Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 26:527-viiiGoogle Scholar
  3. 3.
    Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13:16–24PubMedCrossRefGoogle Scholar
  4. 4.
    Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12PubMedCrossRefGoogle Scholar
  5. 5.
    Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA (2007) Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56:343–357PubMedCrossRefGoogle Scholar
  6. 6.
    Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS (2011) Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71:1029–1040PubMedCrossRefGoogle Scholar
  7. 7.
    Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12:589–603PubMedCrossRefGoogle Scholar
  8. 8.
    Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P (2014) Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clin Cancer ResGoogle Scholar
  9. 9.
    Scagliotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38:292–302PubMedCrossRefGoogle Scholar
  10. 10.
    Chen HX, Sharon E (2013) IGF-1R as an anti-cancer target–trials and tribulations. Chin J Cancer 32:242–252PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Haruo Iguchi
    • 1
  • Tomohiro Nishina
    • 1
  • Naoyuki Nogami
    • 1
  • Toshiyuki Kozuki
    • 1
  • Yumiko Yamagiwa
    • 1
  • Katsuro Yagawa
    • 2
  1. 1.Clinical Research Center, National Hospital Organization Shikoku Cancer CenterMatsuyama CityJapan
  2. 2.AstraZenecaOsakaJapan

Personalised recommendations